An interventional study of FabLife in Male Infertility, sponsored by FabLife. Status unknown at 2 sites in France. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by FabLife · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Infertility, Male with a site in France — 2 open to participants now, 2 under way, none of them phase 3. Infertility, Male · France.
Among the 11 studies in Infertility, Male with a site in France, this one is one of 2 that started in 2018, is one of 6 with no phase, and was the 7th registered.
282 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.
Browse Infertility, Male studies →2 of the 11 studies in Infertility, Male with a site in France are open now. Recruiting first, the newest first:
University Hospital, Brest · Sites in France
Ages 18+ · Men only · Healthy volunteers
GYNOV · Sites in France
Ages 20–45 · Men only · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 40 Infertility, Male studies recruiting now, 16 (40%) set no upper age limit and 24 (60%) stop at 75 or younger; 7 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 45 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is close to the median of 80 across 187 interventional studies indexed under Infertility, Male.
Median enrollment 162 across the 7 interventional studies, 75 across the 4 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 7 most frequent:
This is the only study on the registry with FabLife as lead sponsor.
FabLife has 1 study filed under Infertility, Male — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Infertility, Male with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
FabLife is an interventional, prospective, multicentre, controlled study undertaken in metropolitan France.
The main objective is to evaluate the effect of FabLife personalised program over a period of 15 weeks on the improvement of spermatic DNA fragmentation in subfertile men compared to general dietary recommendations.
More than 15 % of couples couldn't get pregnant after at least a year of unprotected intercourse.
The FabLife personalised program aims to improve sperm quality including sperm DNA fragmentation in subfertile men through:
A total of 75 patients will be recruited:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Conventional spermatic parameters compatible with spontaneous pregnancy
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fablife personnalised support and telephone follow-up with a dietician.
Device: FabLife
General dietary recommendations.
* A personnalized dietary program depending on the patient's phenotype and genotype * The daily intake of a dietary supplement, developped in the context of male infertility.
Sperm DNA fragmentation
Difference in sperm DNA fragmentation from baseline to post-treatment
Time frame: 15 weeks
Semen quality
Difference in semen quality (semen variables including total sperm count, sperm concentration, sperm motility, sperm morphology and semen volume) from baseline to post-treatment.
Time frame: 15 weeks
Sperm motility
Difference in sperm motility from baseline to post-treatment.
Time frame: 15 weeks
Sperm morphology
Difference in sperm morphology from baseline to post-treatment.
Time frame: 15 weeks
Sperm concentration
Difference in sperm concentration from baseline to post-treatment.
Time frame: 15 weeks
Semen volume
Difference in semen volume from baseline to post-treatment.
Time frame: 15 weeks
Total sperm count
Difference in total sperm count from baseline to post-treatment.
Time frame: 15 weeks
Started Feb 2018 (actual). Primary completion is estimated for Jun 2019, 16 months after the start.
Of 92 interventional studies with no phase under Infertility, Male, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.